Search
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigationalSilodosin is a selective antagonist of alpha(α)-1 adrenergic receptors that binds to the α<sub>1A</sub> subtype with the highest affinity. α1-adrenergic receptors regulate smooth muscle tone in the bladder … neck, prostate, and prostatic urethra: the α<sub>1A</sub> subtype accounts for approximately 75% of α1-adrenoceptors in the prostate.
Categories: Heterocyclic Compounds, 2-Ring, Peripheral alpha-1 blockersProducts: SİLODOPİN 4 MG KAPSÜL, 30 ADET, SİLODOPİN 8 MG KAPSÜL, 30 ADETMinocycline
go.drugbank.com/drugs/DB01017ApprovedInvestigational[A190723] Minocycline was granted FDA approval on 30 June 1971.[L11695] … [A190681] It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria.
Synonyms: (4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide, 7-Dimethylamino-6-demethyl-6-deoxytetracyclineProducts: Udima 50 mg - Kapseln, Riva-minocycline 50 mgObinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] It was developed as a Type II anti-CD20 antibody to improve upon first-generation agents like rituximab. … [L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521]
Categories: CD20 (Clusters of Differentiation 20) inhibitorsProducts: GAZYVA ® CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN 1000 MG / VIAL 40 ML, GAZYVA 1000 MG IV İNFÜZYONLUK KONSANTRE ÇÖZELTİ, 1 ADETSunobinop
go.drugbank.com/drugs/DB18955InvestigationalSunobinop is under investigation in clinical trial NCT04035200 (Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation).
Synonyms: 4-((1r,1'r,3r,3'r,5s,5's)-9'-aza(3,9'- bi(bicyclo(3.3.1)nonan))-3'-yl)-3-oxo-3,4- dihydroquinoxaline-2-carboxylic acid, 2-quinoxalinecarboxylic acid, 4-((3-endo)-9-(3-exo)-bicyclo(3.3.1)non-3-yl-9-azabicyclo(3.3.1)non-3-yl)-3,4-dihydro-3-oxo-Levocabastine
go.drugbank.com/drugs/DB01106ApprovedLevocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.
Categories: Heterocyclic Compounds, 1-RingProducts: Levocamed 0,5 mg/ml Augentropfensuspension, Levocamed 0,5 mg/ml Nasenspray, SuspensionPyrazinamide
go.drugbank.com/drugs/DB00339ApprovedInvestigationalA pyrazine that is used therapeutically as an antitubercular agent.
Mixtures: RIFAMPICIN 75 MG/ISONIAZID 50 MG/PYRAZINAMIDE 150 MG, RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MGCategories: Heterocyclic Compounds, 1-RingFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Mixtures: RELVAR ELLIPTA 100/25 MCG KULLANIMA HAZIR INHALASYON TOZU ,3 X 30, RELVAR ELLIPTA 100/25 MCG KULLANIMA HAZIR INHALASYON TOZU ,14 DOZCategories: P-glycoprotein inducers, P-glycoprotein substratesNystatin
go.drugbank.com/drugs/DB00646ApprovedInvestigationalVet approved[L10686] It is one of the most effective antifungal agents synthesized by bacteria, in this case a strain of _Streptomyces noursei_,[L10776] and is closely related to [amphotericin B], differing only slightly … [A188562] Nystatin has a greater antifungal activity than amphotericin B - parenterally administered nystatin, however, is associated with significant toxicity and is not available in a formulation appropriate
Mixtures: NİFUNİS 500 MG/200.000 I.U. VAJİNAL OVÜL, 12 ADET, NİFUNİS 500 MG/200.000 I.U. VAJİNAL OVÜL, 6 ADETCategories: Compounds used in a research, industrial, or household settingEthambutol
go.drugbank.com/drugs/DB00330ApprovedInvestigational[A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967. … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and [pyrazinamide] in the treatment of pulmonary tuberculosis.
Mixtures: RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MG, RIFAMPICIN 150 MG/ISONIAZID 75 MG/PYRAZINAMIDE 400 MG/ETHAMBUTOL 275 MGCategories: MATE 1 Substrates, MATE 2 SubstratesCavrotolimod
go.drugbank.com/drugs/DB18216InvestigationalSynonyms: -CHOLEST-5-EN-3-YLOXY)-19,39,42-TRIHYDROXY-19,39-DIOXIDO-58-OXO-3,6,9,12,15,18,20,23,26,29,32,35,38,40,44,47,50,53-OCTADECAOXA-57-AZA-19,39-DIPHOSPHAOCTAPENTACONT-1-YL HYDR, DNA, D(P-THIO)(T-C-G-T-C-G-T-T-T-T-G-T-C-G-T-T-T-T-G-T-C-G-T-T), 3'-(58-((3.BETA.)